Corvus Pharmaceuticals Inc (NASDAQ:CRVS) insider Richard A. Md Miller purchased 15,212 shares of the business’s stock in a transaction that occurred on Tuesday, June 11th. The shares were purchased at an average cost of $3.49 per share, with a total value of $53,089.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
CRVS stock traded down $0.11 during trading on Friday, hitting $3.53. 7,221 shares of the stock traded hands, compared to its average volume of 69,996. Corvus Pharmaceuticals Inc has a one year low of $3.22 and a one year high of $13.91. The company has a debt-to-equity ratio of 0.03, a current ratio of 12.39 and a quick ratio of 12.39.
Corvus Pharmaceuticals (NASDAQ:CRVS) last announced its quarterly earnings results on Thursday, May 9th. The company reported ($0.40) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.40). On average, research analysts predict that Corvus Pharmaceuticals Inc will post -1.61 EPS for the current year.
Several brokerages recently issued reports on CRVS. Zacks Investment Research downgraded shares of Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, March 20th. Wedbush cut their price target on shares of Corvus Pharmaceuticals from $19.00 to $11.00 and set an “outperform” rating for the company in a report on Wednesday, March 13th. Finally, Roth Capital began coverage on shares of Corvus Pharmaceuticals in a report on Wednesday, May 29th. They set a “buy” rating and a $6.00 price target for the company. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $9.19.
WARNING: This news story was published by Ticker Report and is the sole property of of Ticker Report. If you are reading this news story on another site, it was stolen and republished in violation of US and international trademark and copyright law. The legal version of this news story can be viewed at https://www.tickerreport.com/banking-finance/4371419/corvus-pharmaceuticals-inc-nasdaqcrvs-insider-richard-a-md-miller-acquires-15212-shares.html.
About Corvus Pharmaceuticals
Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint.
Featured Story: The Discount Rate – What You Need to Know
Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.